Six Drug Companies Join New NCI Formulary As Part Of Cancer Moonshot

By Beth Wang / January 12, 2017 at 7:38 PM
The National Cancer Institute announced the launch of a new NCI Formulary intended to provide its cancer center investigators quicker access to laboratory-tested and FDA-approved substances for use in pre-clinical studies and cancer clinical trials. The formulary currently includes 15 targeted agents from six pharmaceutical companies : Bristol-Myers Squibb, Eli Lilly and Company, Genentech, Kyowa Hakko Kirin, Loxo Oncology and Xcovery Holding Company LLC. “The agreements with these companies demonstrate our shared commitment to expedite cancer clinical trials and improve...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.